---

Approach to Volume Overload States

---

1. Definition & Pathophysiology

• Impaired renal sodium excretion is the final common pathway in most causes
• Reduced effective arterial blood volume (EABV) → baroreceptor activation → RAAS, SNS, ADH upregulation → avid renal Na⁺ and water retention
• In heart failure and cirrhosis, despite total body Na excess, the EABV is perceived as low, perpetuating sodium retention
• In CKD, reduced nephron mass directly limits natriuretic capacity
• In nephrotic syndrome, two mechanisms operate: underfill (hypoalbuminemia → reduced oncotic pressure) and primary overfill (intrinsic renal ENaC activation by filtered plasmin)

---

2. Clinical Assessment

History

• Dyspnea (exertional, orthopnea, PND), leg swelling, weight gain, abdominal distension
• Reduced urine output
• Relevant history: heart failure, liver disease, renal disease, nephrotic syndrome
• Recent dietary salt intake, medication changes (NSAIDs, steroids, CCBs)

Physical Examination

• Dependent pitting edema (ankles/sacrum)
• Ascites: shifting dullness (LR+ 2.3), fluid thrill (LR+ 9.6)
• Pleural effusion: dullness to percussion, reduced breath sounds
• Pulmonary edema: bilateral crackles, hypoxia
• Assess skin turgor, mucous membranes, and capillary refill to distinguish from dehydration

Investigations

---

3. Causes and Classification

Edema-forming States (Pathophysiologic Framework)

---

4. Stepwise Management Approach

General Principles

1. Treat the underlying cause
2. Restrict dietary sodium (<2 g/day; <1 g/day in severe cases)
3. Fluid restriction when hyponatremia is present (typically <1.5 L/day)
4. Diuresis: loop diuretics are the cornerstone

---

Diuretic Therapy

Loop Diuretics (First-Line)

• Start at the equivalent of the patient's outpatient oral dose (or higher in acute decompensation)
• If no response within 2 hours (urine output <200 mL), double the dose
• In CKD: doses of furosemide 160–240 mg IV may be needed to achieve adequate tubular levels

Combination Diuretic Therapy (Sequential Nephron Blockade)

---

5. Diuretic Resistance

Definition

Causes

Management Algorithm for Diuretic Resistance

Step 1: Confirm adequate IV dosing (switch oral → IV)
Step 2: Optimize renal perfusion (treat hypo-perfusion, hold nephrotoxins)
Step 3: Add metolazone or thiazide (sequential nephron blockade)
Step 4: Add aldosterone antagonist (if not already on)
Step 5: Consider acetazolamide (if metabolic alkalosis present)
Step 6: Consider ultrafiltration / aquapheresis
Step 7: Hemodynamic monitoring (Swan-Ganz) if etiology unclear

---

6. Monitoring and Endpoints

Targets of Decongestion

• Weight loss of 0.5–1 kg/day (up to 1.5 kg/day in severe cases)
• Urine output goal: >0.5 mL/kg/hr (or >1 L net negative per day)
• Resolution of orthopnea, JVP normalization, resolution of peripheral edema

Labs to Monitor

• Daily: electrolytes (Na⁺, K⁺, Mg²⁺), BUN, creatinine, weight
• BNP trend: declining BNP during hospitalization associated with better outcomes
• Watch for: hypokalemia (target K⁺ >4.0 mEq/L in HF), hyponatremia, hypomagnesemia, metabolic alkalosis, hyperuricemia, azotemia

When to Ease Diuresis

• Rising creatinine >0.3 mg/dL above baseline with clinical evidence of euvolemia
• Symptomatic hypotension
• Severe electrolyte disturbances

---

7. Special Populations

Heart Failure (HFrEF/HFpEF)

• Neurohormonal blockade is essential: ACEi/ARB/ARNI + beta-blocker + MRA + SGLT2i (reduce hospitalizations and mortality)
• SGLT2 inhibitors (dapagliflozin, empagliflozin) have osmotic diuretic effects and reduce HF hospitalization independent of diabetes
• Torsemide preferred over furosemide due to superior bioavailability
• Aquapheresis/ultrafiltration: consider in refractory cases; removes isotonic fluid but CARRESS-HF trial showed no advantage over stepped pharmacotherapy and higher creatinine — reserve for true refractory cases
• Target pre-discharge optimization: JVP <8 cm, no orthopnea, minimal peripheral edema, BNP trend declining

Cirrhosis with Ascites (AASLD Guidelines)

• Grade 1 (mild): sodium restriction alone
• Grade 2 (moderate): Spironolactone 100 mg + Furosemide 40 mg daily (maintain 2.5:1 ratio to prevent hypokalemia)
• Titrate up to Spironolactone 400 mg + Furosemide 160 mg as needed
• Large-volume paracentesis (LVP): first-line for tense ascites; always give albumin 8 g per liter of ascitic fluid removed to prevent post-paracentesis circulatory dysfunction
• TIPS (Transjugular Intrahepatic Portosystemic Shunt): for refractory ascites; reduces portal hypertension; contraindicated in hepatic encephalopathy, advanced HF
• Avoid: NSAIDs, aminoglycosides, ACE inhibitors (risk of AKI and hepatorenal syndrome)
• Hepatorenal syndrome: terlipressin + albumin (evidence-based); norepinephrine + albumin as alternative

Nephrotic Syndrome

• Primary sodium restriction + dietary protein optimization
• Loop diuretics often require high doses due to albumin binding → less free drug in tubular lumen
• Combination with albumin infusion can improve diuretic delivery (IV albumin 25 g + furosemide 80–120 mg; evidence is mixed but used in practice)
• Address underlying cause (corticosteroids, immunosuppressants for minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy)
• RAAS blockade reduces proteinuria and helps manage volume

CKD Stages 3b–5 (Non-Dialysis)

• Higher doses of loop diuretics required (tubular secretion proportional to GFR)
• Furosemide 160–500 mg/day in advanced CKD (GFR <30 mL/min)
• Metolazone remains effective at low GFR — use cautiously (risk of overcorrection)
• Preserve residual renal function: avoid nephrotoxins, optimize BP
• SGLT2 inhibitors (particularly in CKD with proteinuria): slow progression and reduce volume

Dialysis Patients

• Hemodialysis: fluid removal via ultrafiltration; target interdialytic weight gain <1 kg/day; residual urine output preserved with loop diuretics as long as residual kidney function persists
• Peritoneal dialysis: icodextrin (7.5% glucose polymer) as osmotic agent for long dwells enhances fluid removal; superior to glucose for ultrafiltration in patients with high peritoneal transport; step up osmotic strength of PD fluid as needed
• Avoid excessive ultrafiltration rates (>13 mL/kg/hr) — associated with intradialytic hypotension and cardiovascular harm

AKI with Oliguria

• Volume optimization is critical — assess hemodynamic status carefully (tissue hypoperfusion → prerenal component may coexist with intrinsic AKI)
• No evidence that furosemide converts oliguric AKI to non-oliguric AKI or improves outcomes — use only for volume management, not renoprotection
• If persistent oliguria despite adequate volume status: prepare for renal replacement therapy (CRRT/HD)

---

8. Complications of Diuretic Therapy

---

Key Clinical Pearls

• Assess, don't guess: Use POCUS, BNP, and clinical examination together — no single test is definitive.
• Route matters in HF: Oral furosemide bioavailability drops from ~50% to as low as 10–20% in acute decompensated HF due to bowel edema — always use IV in acute admissions.
• Torsemide preferred over furosemide in chronic HF management due to better and more consistent bioavailability (~80%) and longer duration of action.
• Sequential nephron blockade: Adding metolazone to a loop diuretic is highly effective but can cause rapid, dramatic electrolyte shifts — monitor closely (daily electrolytes) within 24–48h of initiation.
• The "braking phenomenon": With prolonged loop diuretic use, compensatory hypertrophy of the distal convoluted tubule increases Na reabsorption downstream — the rationale for adding a DCT blocker.
• Don't confuse dehydration with decongestion: A patient can be volume-overloaded yet intravascularly deplete (cirrhosis, nephrotic syndrome) — aggressive diuresis in this setting causes AKI and hemodynamic compromise.
• SGLT2 inhibitors are now standard of care in both HFrEF and HFpEF — their osmotic diuresis is gradual and self-limiting (reducing hypotension risk) while providing durable decongestion.

---

---

Approach to Volume Overload States

Based on Standard Medical Textbooks & Guidelines

---

1. Definition & Pathophysiology

The Effective Arterial Blood Volume (EABV) Concept

State-Specific Mechanisms

---

2. Clinical Assessment

History

• Symptoms: dyspnea (exertional → orthopnea → PND → rest), leg swelling, abdominal distension, early satiety, reduced urine output, rapid weight gain
• Establish underlying etiology: HF, liver disease, CKD, nephrotic syndrome, recent IV fluids/transfusion
• Provocants: dietary Na excess, NSAID use, missed diuretics, new CCB, corticosteroids, thiazolidinediones

Physical Examination

• Assess JVP at 45° — estimated CVP; measure vertical height above sternal angle + 5 cm
• Sacral edema in bed-bound patients (don't miss — check the sacrum)
• Assess for pleural dullness bilaterally
• Distinguish cardiac (bilateral, symmetric edema + elevated JVP) from hepatic (ascites dominant + stigmata of liver disease) from nephrotic (periorbital edema, frothy urine, bilateral leg edema + no elevated JVP)

Investigations

---

3. Differential Diagnosis — Causes of Volume Overload

Clinical trap: CCB-induced edema is due to precapillary vasodilation redistributing fluid to interstitium — it is NOT diuretic-responsive. The treatment is switching or reducing the CCB.

---

4. General Management Principles

1. Identify and treat the underlying cause (optimize HF therapy, manage cirrhosis, treat nephrotic syndrome)
2. Dietary sodium restriction: <2 g/day (88 mmol/day); <1.5 g/day in refractory cases
3. Fluid restriction: Indicated when hyponatremia is present (Na <130 mEq/L); typically 1–1.5 L/day
4. Posture: Leg elevation promotes venous return and mobilizes dependent edema
5. Compression stockings: Useful adjunct in chronic venous edema (not in acute HF)
6. Optimize hemodynamics before aggressive diuresis: ensure adequate blood pressure and perfusion (MAP >65 mmHg; treat cardiorenal syndrome type 1 carefully)
7. Hold/review nephrotoxins and Na-retaining medications (NSAIDs, contrast agents, aminoglycosides)

---

5. Diuretic Therapy

Loop Diuretics — First-Line

• In acute decompensated HF (ADHF): use IV (oral furosemide bioavailability drops to 10–30% due to bowel edema)
• Start at a dose ≥ the patient's outpatient oral dose (or 2.5× outpatient dose in ADHF — DOSE trial)
• If urine output <200 mL in 2 hours after IV dose, double the dose
• In CKD (GFR <30): furosemide 160–250 mg IV per dose may be required to achieve adequate tubular drug levels

• High-dose (2.5× oral equivalent IV) vs. low-dose: no difference in creatinine at 72h; high-dose → greater symptom relief and net fluid loss
• Continuous infusion vs. bolus q12h: no significant difference in outcomes or safety
• Practical implication: high-dose IV bolus is appropriate in ADHF; continuous infusion is an acceptable alternative

Thiazide and Thiazide-like Diuretics

Potassium-Sparing Diuretics

Carbonic Anhydrase Inhibitors

Sequential Nephron Blockade (Combination Diuretic Therapy)

Loop diuretic (thick ascending limb)
    + Metolazone or HCTZ (distal tubule)
    + Spironolactone/eplerenone (collecting duct)
    ± Acetazolamide (proximal tubule, if metabolic alkalosis)

Add metolazone 30–60 minutes before the loop diuretic dose. Monitor electrolytes within 24–48 hours — rapid, profound shifts in K⁺, Na⁺, Mg²⁺ can occur.

---

6. Diuretic Resistance

Definition

Mechanisms

Stepwise Management of Diuretic Resistance

Step 1:  Confirm IV route — switch oral → IV furosemide
Step 2:  Increase dose (double until adequate response or max dose)
Step 3:  Add metolazone 2.5–10 mg PO 30 min before loop diuretic
Step 4:  Add or increase aldosterone antagonist (spironolactone 50–200 mg)
Step 5:  Add acetazolamide 500 mg if metabolic alkalosis present
Step 6:  Correct hypoalbuminemia; consider IV albumin + furosemide
Step 7:  Optimize hemodynamics (vasodilators in HF, midodrine in cirrhosis)
Step 8:  Consider ultrafiltration / renal replacement therapy
Step 9:  Hemodynamic monitoring (PA catheter) if refractory and unclear filling pressures

---

7. Renal Replacement Therapy (RRT)

Absolute Indications for RRT in Volume Overload Context

• Volume overload unresponsive to diuretic therapy
• Persistent hyperkalemia despite medical therapy
• Severe metabolic acidosis
• Overt uremic symptoms (encephalopathy, pericarditis, uremic bleeding)

Modalities

---

8. Special Populations

Heart Failure (HFrEF and HFpEF)

• IV loop diuretic immediately on admission
• Target: net fluid loss 1–2 L/day; weight loss 0.5–1 kg/day
• Reassess at 6h: if urine output <1 mL/kg/hr → increase dose
• Avoid excessive diuresis (MAP <65 or rising Cr >0.5 mg/dL above baseline)

• ACEi/ARB/ARNI (sacubitril-valsartan) — reduces mortality, hospitalizations
• Beta-blocker — carvedilol, metoprolol succinate, bisoprolol
• MRA — spironolactone/eplerenone (RALES, EPHESUS, EMPHASIS-HF)
• SGLT2 inhibitors — dapagliflozin (DAPA-HF), empagliflozin (EMPEROR-Reduced): reduce HF hospitalizations and mortality in both HFrEF and HFpEF; provide osmotic diuresis without electrolyte disturbance

• Torsemide preferred over furosemide in chronic management (80% bioavailability, longer action, possible mortality benefit — TRANSFORM-HF trial under analysis)
• Switch furosemide → torsemide in patients with recurrent HF hospitalizations

Cirrhosis with Ascites (AASLD / International Ascites Club Guidelines)

• Maintain spironolactone:furosemide = 100:40 ratio to preserve normokalemia
• Maximum doses: spironolactone 400 mg + furosemide 160 mg/day
• Never give NSAIDs — risk of AKI and hepatorenal syndrome (HRS)
• Avoid ACEi/ARBs in ascitic patients — precipitates HRS
• HRS treatment: terlipressin 1–2 mg q4–6h + albumin 1 g/kg on day 1 then 20–40 g/day (CONFIRM trial); norepinephrine + albumin as alternative

Nephrotic Syndrome

• Sodium restriction + loop diuretics; typically require high doses due to:
  • Urinary loss of albumin-bound furosemide → less free drug in tubule
  • Primary ENaC activation by filtered plasmin → downstream Na reclamation
• Amiloride is particularly useful (directly blocks ENaC overactivity)
• IV albumin 25 g immediately before IV furosemide in severely hypoalbuminemic patients (albumin <2 g/dL) — increases delivered drug; evidence is mixed but clinically used
• Treat underlying glomerular disease: corticosteroids (MCD), rituximab (MCD relapse), calcineurin inhibitors (FSGS), immunosuppression (MN)
• RAAS blockade (ACEi/ARB) reduces proteinuria and slows CKD progression

CKD (Non-Dialysis, Stages 3b–5)

• Loop diuretics remain effective even at low GFR, but higher doses needed (tubular secretion proportional to GFR)
• Furosemide doses of 160–500 mg/day may be required in GFR <15 mL/min
• Metolazone is effective even in severe CKD — use cautiously
• SGLT2 inhibitors (dapagliflozin, empagliflozin): now indicated in CKD with proteinuria (CREDENCE, DAPA-CKD trials) — slow progression and reduce volume-related hospitalizations
• Avoid thiazides (HCTZ, chlorthalidone) when GFR <30 as monotherapy (exception: chlorthalidone may retain some efficacy at lower GFR based on recent data)

Dialysis Patients

• Fluid removal by ultrafiltration; ideal: keep interdialytic weight gain <1 kg/day
• Avoid UF rates >13 mL/kg/hr — associated with intradialytic hypotension, myocardial stunning, CV mortality
• Preserve residual kidney function (RKF): continue loop diuretics as long as there is any urine output (furosemide high-dose)
• Avoid nephrotoxins; sodium profiling in HD helps reduce intradialytic symptoms

• Use icodextrin (7.5%) for long dwells (overnight) — glucose polymer, maintains sustained osmotic gradient unlike hypertonic glucose; particularly effective in high-transport patients
• Step up glucose concentration (1.36% → 2.27% → 3.86%) as needed
• PD drainage failure: check for fibrin/obstruction; thrombolytic flush
• Per Comprehensive Clinical Nephrology: if RKF >100 mL/day and volume overload persists → loop diuretic furosemide 320–400 mg/day in divided doses ± metolazone

AKI with Oliguria

• First: distinguish prerenal (volume depletion/low perfusion) from intrinsic AKI — do NOT diurese a volume-depleted AKI patient
• If volume overloaded + intrinsic AKI: judicious diuresis for symptom relief; no evidence that converting oliguric → non-oliguric AKI improves outcomes (do not use furosemide for renoprotection)
• If oliguria persists despite euvolemia: prepare for RRT

---

9. Monitoring & Endpoints of Decongestion

Clinical Targets

• Weight loss: 0.5–1.0 kg/day (up to 1.5 kg/day in tense ascites or severe HF)
• Urine output: >1 mL/kg/hr or net negative >1 L/day
• Resolution of orthopnea, normalization of JVP (<8 cm H₂O), clearing of pulmonary crackles, reduction in peripheral edema
• POCUS B-lines: target <3 per zone before discharge

Laboratory Monitoring

When to Ease or Stop Diuresis

• Clinical signs of volume depletion (orthostatic hypotension, dry mucous membranes, tachycardia)
• Creatinine rise >0.5 mg/dL above baseline without clinical evidence of residual congestion
• Hyponatremia worsening (Na <128 mEq/L)
• Symptomatic hypotension

---

10. Complications of Diuretic Therapy

---

Key Clinical Pearls

---